NASDAQ
13.11.25 | 21:59
1,215 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Jefferies initiates coverage on ALX Oncology stock with Buy rating | 1 | Investing.com | ||
| 07.11. | ALX Oncology anticipates $2B-$4B HER2/CD47 breast cancer market opportunity while advancing biomarker-driven strategies | 6 | Seeking Alpha | ||
| 07.11. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Earnings Call Transkript: ALX Oncology zeigt vielversprechende Fortschritte bei Medikamentenentwicklung in Q3 2025 | 2 | Investing.com Deutsch | ||
| 07.11. | ALX Oncology GAAP EPS of -$0.41 misses by $0.04 | 3 | Seeking Alpha | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 07.11. | ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 124 | GlobeNewswire (Europe) | ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast... ► Artikel lesen | |
| 07.11. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 06.11. | Examining the Future: ALX Oncology Holdings' Earnings Outlook | 2 | Benzinga.com | ||
| 23.10. | Alx Oncology stock jumps after presenting preclinical ADC data at conference | 3 | Investing.com | ||
| 23.10. | Präklinische ADC-Daten beflügeln Aktie von Alx Oncology | 1 | Investing.com Deutsch | ||
| 23.10. | ALX Oncology stellt präklinische Daten für neuartigen EGFR-Krebswirkstoff vor | 7 | Investing.com Deutsch | ||
| 23.10. | ALX Oncology presents preclinical data for novel EGFR cancer drug | 1 | Investing.com | ||
| 03.10. | ALX Oncology to present CD47 biomarker data for evorpacept at SITC | 1 | Investing.com | ||
| 03.10. | ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 12.09. | ALX Oncology appoints board member Klencke as interim CMO | 2 | Investing.com | ||
| 12.09. | ALX Oncology CMO Alan Sandler Resigns; Appoints Board Member Barbara Klencke As Interim CMO | 1 | RTTNews | ||
| 12.09. | ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer | 237 | GlobeNewswire (Europe) | Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from... ► Artikel lesen | |
| 12.09. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | ALX Oncology doses first patient in phase 1 trial of EGFR cancer drug | 1 | Investing.com | ||
| 12.08. | ALX Oncology Q2 2025 slides: biomarker strategy shows promise as cash runway extends | 6 | Investing.com |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,138 | -5,76 % | Nel ASA: Insider kauft Aktien - Evotec, Newron, Rheinmetall, SUSS und ThyssenKrupp im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| MODERNA | 21,030 | -4,32 % | Moderna, Inc. - 8-K, Current Report | ||
| NOVAVAX | 5,921 | -2,50 % | NOVAVAX INC steht still - ich rieche gewaltige Bewegung! | ||
| CRISPR THERAPEUTICS | 42,800 | -2,73 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,660 | -1,78 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,282 | -2,23 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,528 | +1,93 % | Defence Therapeutics Inc.: Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs | Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation... ► Artikel lesen | |
| EDITAS MEDICINE | 2,056 | -5,86 % | Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y | ||
| SAREPTA THERAPEUTICS | 14,805 | -3,46 % | Aktien New York: Anleger realisieren Gewinne nach Rekordlauf | NEW YORK (dpa-AFX) - Nach ihrem jüngsten Rekordkurs haben die Anleger an den US-Aktienmärkten am Dienstag Druck aus dem Kessel gelassen. Die Investoren hinterfragten zunehmend die hohen Bewertungen... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,830 | +0,47 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| EXELIXIS | 34,500 | -5,22 % | Adagene Inc.: Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate | SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis.... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,310 | -5,62 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 61,56 | +0,59 % | Plattform statt Risiko: Halozyme auf dem Weg in die Zukunft? | Ausstieg aus der eigenen Forschung, Fokus auf Plattformtechnologie - Halozyme zeigt, wie kluges Strategie-Management aussieht Den vollständigen Artikel lesen ... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 124,25 | +0,24 % | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder | SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and... ► Artikel lesen | |
| VAXART | 0,352 | +27,91 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,215 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.